Product Code: 1884
Over the Counter (OTC) Drugs Market is slated to witness massive growth through 2032, mainly owing to the increasing affordability of OTC drugs for both the consumers as well as for the healthcare system across the globe.
In addition, Rx to OTC switch results in greater availability and sales due to easy off-the-shelf availability, better accessibility, and cost-effectiveness.
Several key players operating in the over the counter (OTC) drugs market are incorporating strategic initiatives like acquisitions, mergers, and product developments to strengthen their foothold in the industry.
For instance, in May 2022, Bayer Healthcare entered into a partnership agreement with Alibaba Health to promote and distribute consumer health products and solutions. This supported the firm expand its capabilities and market share in the industry.
Overall, the over the counter (OTC) drugs market is bifurcated in terms of product, distribution channel, and regional landscape.
By product, the cold, cough & flu products segment recorded a revenue of more than USD 30 billion in 2022 and is poised to grow exponentially by 2032. The segmental growth will be attributed to the rising incidence of cold & flu among the population and increased awareness and preferences about self-medication treatment.
The skin products segment is also expected to register strong growth by 2032, owing to consumers' rising inclination and preference towards several beauty products such as serums, creams, and moisturizers. In addition, rising consciousness regarding one's physical appearance, especially among the female population, will further push the segment's growth.
By distribution channel, the hospital pharmacy segment is expected to account for 27% market share by 2032. Hospital pharmacy offers better patient counseling for authentic products. Along with this, the availability of various products in the market will propel the segment share in the coming future.
Considering the regional perspective, the North America over the counter (OTC) drugs market held a substantial market share of more than 25% in 2022 and is predicted to grow significantly through 2032. The regional growth will be attributed to the rising acceptance of OTC drugs by consumers in the North American economies combined with the established regulatory authorities.
Some of the key players operating in the market are Johnson & Johnson Services Inc., GlaxoSmithKline Plc., Bayer AG, Sanofi, The Blackstone Group, Inc. (Alinamin Pharmaceutical Co., Ltd.), Piramal Enterprises Limited, Sun Pharmaceutical Industries Ltd., Cipla, Inc., Alkem Laboratories Limited., Reckitt Benckiser Group Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., and Dr. Reddy's Laboratories, Viatris, Inc.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market definations
- 1.2 Base estimates and working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia pacific
- 1.2.4 Latin America
- 1.2.5 MEA
- 1.3 Forecast calculations
- 1.4 Data validation
- 1.5 Data sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Unpaid sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Over the counter (OTC) drugs market industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Product trends
- 2.1.3 Distribution channel trends
- 2.1.4 Regional trends
Chapter 3 Over the Counter (OTC) Drugs Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2018 - 2032
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Pharmaceutical companies switching from Rx to OTC drugs especially in the U.S
- 3.3.1.2 Growing trend of self-medication in developing economies
- 3.3.1.3 Significant cost savings due to OTC drug usage in Asia Pacific and Latin America
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Several concerns pertaining to incorrect diagnosis and substance abuse
- 3.4 Growth potential analysis
- 3.4.1 By product
- 3.4.2 By distribution channel
- 3.5 COVID- 19 impact analysis
- 3.6 Regulatory landscape
- 3.7 Porter's analysis
- 3.7.1 Bargaining power of suppliers
- 3.7.2 Bargaining power of buyers
- 3.7.3 Threat of new entrants
- 3.7.4 Threat of substitutes
- 3.7.5 Industry rivalry
- 3.8 PESTLE analysis
- 3.8.1 Political
- 3.8.2 Economical
- 3.8.3 Social
- 3.8.4 Technological
- 3.8.5 Legal
- 3.8.6 Environmental
Chapter 4 Competitive Landscape, 2021
- 4.1 Introduction
- 4.1.1 Company 1
- 4.1.2 Company 2
- 4.1.3 Company 3
- 4.2 Company matrix analysis, 2021
- 4.3 Strategy dashboard, 2021
Chapter 5 Over the Counter (OTC) Drugs Market, By Product
- 5.1 Key segment trends
- 5.2 Analgesics
- 5.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.3 Cold, cough & flu products
- 5.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.4 Weight loss products
- 5.4.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.5 Gastrointestinal products
- 5.5.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.6 Skin products
- 5.6.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.7 Minerals and vitamin supplements
- 5.7.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.8 Sleeping aids
- 5.8.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.9 Ophthalmic products
- 5.9.1 Market size, by region, 2018 - 2032 (USD Million)
- 5.10 Others
- 5.10.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 6 Over the Counter (OTC) Drugs Market, By Distribution Channel
- 6.1 Key segment trends
- 6.2 Hospital pharmacy
- 6.2.1 Market size, by region, 2018 - 2032 (USD Million)
- 6.3 Retail pharmacy
- 6.3.1 Market size, by region, 2018 - 2032 (USD Million)
- 6.4 Online medstores
- 6.4.1 Market size, by region, 2018 - 2032 (USD Million)
- 6.5 Others
- 6.5.1 Market size, by region, 2018 - 2032 (USD Million)
Chapter 7 Over the Counter (OTC) Drugs Market, By Region
- 7.1 Key regional trends
- 7.2 North America
- 7.2.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.2.2 Market size, by product, 2018 - 2032 (USD Million)
- 7.2.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.2.4 U.S.
- 7.2.4.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.2.4.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.2.5 Canada
- 7.2.5.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.2.5.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3 Europe
- 7.3.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.3.2 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.4 Germany
- 7.3.4.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.4.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.5 UK
- 7.3.5.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.5.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.6 France
- 7.3.6.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.6.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.7 Italy
- 7.3.7.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.7.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.8 Spain
- 7.3.8.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.8.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.9 Russia
- 7.3.9.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.9.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.3.10 Poland
- 7.3.10.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.3.10.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4 Asia Pacific
- 7.4.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.4.2 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.4 China
- 7.4.4.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.4.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.5 Japan
- 7.4.5.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.5.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.6 India
- 7.4.6.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.6.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.7 Australia
- 7.4.7.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.7.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.8 South Korea
- 7.4.8.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.8.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.4.9 Taiwan
- 7.4.9.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.4.9.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.5 Latin America
- 7.5.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.5.2 Market size, by product, 2018 - 2032 (USD Million)
- 7.5.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.5.4 Brazil
- 7.5.4.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.5.4.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.5.5 Mexico
- 7.5.5.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.5.5.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.5.6 Argentina
- 7.5.6.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.5.6.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6 Middle East & Africa
- 7.6.1 Market size, by country, 2018 - 2032 (USD Million)
- 7.6.2 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.3 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6.4 South Africa
- 7.6.4.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.4.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6.5 Saudi Arabia
- 7.6.5.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.5.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6.6 Qatar
- 7.6.6.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.6.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6.7 Nigeria
- 7.6.7.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.7.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
- 7.6.8 Kuwait
- 7.6.8.1 Market size, by product, 2018 - 2032 (USD Million)
- 7.6.8.2 Market size, by distribution channel, 2018 - 2032 (USD Million)
Chapter 8 Company Profiles
- 8.1 Bayer AG.
- 8.1.1 Business overview
- 8.1.2 Financial data
- 8.1.3 Product landscape
- 8.1.4 Strategic outlook
- 8.1.5 SWOT analysis
- 8.2 GlaxoSmithKline (GSK).
- 8.2.1 Business overview
- 8.2.2 Financial data
- 8.2.3 Product landscape
- 8.2.4 Strategic outlook
- 8.2.5 SWOT analysis
- 8.3 Sanofi
- 8.3.1 Business overview
- 8.3.2 Financial data
- 8.3.3 Product landscape
- 8.3.4 Strategic outlook
- 8.3.5 SWOT analysis
- 8.4 Johnson & Johnson
- 8.4.1 Business overview
- 8.4.2 Financial data
- 8.4.3 Product landscape
- 8.4.4 Strategic outlook
- 8.4.5 SWOT analysis
- 8.5 Sun Pharmaceutical Industries Ltd
- 8.5.1 Business overview
- 8.5.2 Financial data
- 8.5.3 Product landscape
- 8.5.4 Strategic outlook
- 8.5.5 SWOT analysis
- 8.6 Alkem Laboratories Limited
- 8.6.1 Business overview
- 8.6.2 Financial data
- 8.6.3 Product landscape
- 8.6.4 Strategic outlook
- 8.6.5 SWOT analysis
- 8.7 Cipla, Inc
- 8.7.1 Business overview
- 8.7.2 Financial data
- 8.7.3 Product landscape
- 8.7.4 Strategic outlook
- 8.7.5 SWOT analysis
- 8.8 Reckitt Benckiser Group Plc.
- 8.8.1 Business overview
- 8.8.2 Financial data
- 8.8.3 Product landscape
- 8.8.4 Strategic outlook
- 8.8.5 SWOT analysis
- 8.9 Piramal Enterprises Limited
- 8.9.1 Business overview
- 8.9.2 Financial data
- 8.9.3 Product landscape
- 8.9.4 Strategic outlook
- 8.9.5 SWOT analysis
- 8.10 Teva Pharmaceutical Industries Ltd
- 8.10.1 Business overview
- 8.10.2 Financial data
- 8.10.3 Product landscape
- 8.10.4 Strategic outlook
- 8.10.5 SWOT analysis
- 8.11 Glenmark Pharmaceuticals Ltd
- 8.11.1 Business overview
- 8.11.2 Financial data
- 8.11.3 Product landscape
- 8.11.4 Strategic outlook
- 8.11.5 SWOT analysis
- 8.12 The Blackstone Group, Inc. (Alinamin Pharmaceutical Co., Ltd.)
- 8.12.1 Business overview
- 8.12.2 Financial data
- 8.12.3 Product landscape
- 8.12.4 Strategic outlook
- 8.12.5 SWOT analysis
- 8.13 Aytu Biopharma, Inc. (Aytu Consumer Health, Inc.)
- 8.13.1 Business overview
- 8.13.2 Financial data
- 8.13.3 Product landscape
- 8.13.4 Strategic outlook
- 8.13.5 SWOT analysis
- 8.14 Dr. Reddy's Laboratories
- 8.14.1 Business overview
- 8.14.2 Financial data
- 8.14.3 Product landscape
- 8.14.4 Strategic outlook
- 8.14.5 SWOT analysis
- 8.15 Viatris, Inc. (Mylan, Inc.)
- 8.15.1 Business overview
- 8.15.2 Financial data
- 8.15.3 Product landscape
- 8.15.4 Strategic outlook
- 8.15.5 SWOT analysis